Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Aera Therapeutics

Company Type: Therapeutics

Main focus: Protein nanoparticles (PNP)

Company stage: Pre-clinical

Diseases: Multiple malignancies, including solid tumours

Genome-editing tool: Licensed therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene-editing enzymes

Funding stage: Series B

Location: Cambridge, Massachusetts, USA


Pipeline: Not disclosed


Aera Therapeutics is an R&D company leveraging its proprietary protein nanoparticle (PNP) delivery platform. PNPs are derived from retroelements that self-assemble to form capsid-like structures, which can package and transfer nucleic acid cargo. This platform can deliver a variety of cargos including siRNAs and CRISPR/Cas-based platforms regardless of the payload size, and thus holds potential for the development of potent genetic therapeutics.


HashtagAera Therapeutics

Company: Aera Therapeutics
Search CRISPR Medicine